A company with a small molecule cancer treatment to combat solid tumor cancers as well as hematological malignancies has raised $5 million in a combination of debt, options and warrants, according to a Form D filing with the Securities and Exchange Commission. The financing will help advance the company’s treatment currently being used in Phase 1, Phase 1b and Phase 2 clinical trials.
Malvern, Pennsylvania-based TetraLogic Pharmaceuticals‘ cancer therapeutic Birinapant reprograms cancer cells, undermining their ability to increase by neutralizing inhibitors of apopteosis proteins that block tumor cell death. That causes executioner proteins, referred to as “caspases,” to instigate cell death for cancer cells.
TetraLogic Pharmaceuticals said on its website that its Birinapant therapeutic caused tumor regression as a single agent and has “potent anti-tumor activity” when it’s combined with chemotherapies and death receptor ligands in preclinical studies. Ligands are ions or molecules bound to a metal atom. To instigate programmed cell death, it’s possible to increase the number of death receptor ligands.
Behavioral Health, Interoperability and eConsent: Meeting the Demands of CMS Final Rule Compliance
In a webinar on April 16 at 1pm ET, Aneesh Chopra will moderate a discussion with executives from DocuSign, Velatura, and behavioral health providers on eConsent, health information exchange and compliance with the CMS Final Rule on interoperability.
The latest financing follows a $6 million fresh capital raise last year. In October 2010, it raised $32 million in a Series C round.
Among the company’s institutional investors are Clarus Ventures, HealthCare Ventures, Quaker Partners, Novitas Capital, Nextech Invest Ltd, Hatteras Venture Partners, Pfizer Ventures, Latterell Venture Partners, the Vertical Group, Amgen Ventures and Kammerer Associates.
In addition to a Phase 2 study for ovarian cancer, the therapeutic is also being used in separate clinical trials with Gemcitabine, FOLFIRI and Bevacizumab and in a Phase 2a study with Irinotecan to combat solid cancer tumors.
